BOC Sciences integrates the antibody-drug conjugate services to offer comprehensive one-stop antibody-drug conjugate research and evaluation services. As a research-oriented and customer-based company, we are committed to helping global customers expedite ADC drug development and manufacture cost-effectively. In BOC Sciences, our customers know us as a professional and attentive partner who delivers quality results, and our services are designed to ensure each project goal is met and exceeded.
Combining monoclonal antibodies (mAb) targeting cancer-specific antigen with cytotoxin has revealed great potential as a novel targeted cancer therapy. Antibody-Drug Conjugates (ADCs) are a new class of therapeutic agents that contain the targeting ability of mAbs with small molecular drugs. Due to the significant differences in ADCs drug designs, including the differences in recognition sites, connection sites, linker design, and small-molecule toxins, the ADCs drugs' overall efficacies and toxicities of the same target may not be the same. The complete development process of ADCs drugs from preclinical to clinical involves target verification, process characterization, preclinical efficacy and safety evaluation, pharmacokinetic model, clinical design, and efficacy evaluation.
A suitable selection of components is the key to successful ADCs development. In order to achieve specific delivery of a cytotoxic payload, target antigen must be highly expressed on the surface of tumor cells rather than the normal cells. Thus, conjugating mAbs to highly potent cytotoxic payloads facilitates site-specific delivery to the target cells and minimizes off-target rate cytotoxicity. Upon binding to the specific antigen, antibodies were absorbed through rapid internalization followed by lysosomal degradation and subsequently releasing cytotoxins inside the cell. As a result, ADCs can be used to deliver cytotoxic drugs to cancer cells.
Mature linker and cytotoxin synthesis technology
High quality, low-cost products - most products are in stock
Milligram to gram laboratory-scale (mg to g)
TGA, 13C-NMR, 1H-NMR, HPLC, MS, GC, and IR
Batch production according to specific needs
With our state-of-the-art equipment and extensive R&D expertise, BOC Sciences can provide customized antibody modification and conjugation technologies with high specificity and affinity with a quick turnaround time. The conjugation method can directly affect the ADC's quality, thereby regulating the safety and efficacy of products. Some strategies for antibody modification and conjugation include:
ADCs are complex molecules with unique critical quality attributes (CQAs). BOC Sciences used to analyze and characterize the antibody-drug conjugate is divided into three modules, which measure the structural characterization, drug effect, and drug impurities of antibody-conjugated drugs to ensure comprehensive analysis and evaluation of ADCs structures and drug effects. Our quality assessment services include:
BOC Sciences' ADC manufacturing platform provides various effective payloads development services ranging from laboratory scale (mg to g) to GMP production (kg). We provide payloads for various targets according to the needs of customers, including microtubule inhibitors, DNA inhibitors, RNA polymerase inhibitors, protein toxins, and enzyme toxins. Our payloads development services include:
Linkers are essential parts of ADCs, which connect mAbs to payloads and stabilize circulation until ADCs reach target cells for payload releases. BOC Sciences offers flexible ADC linker product suites and development services at competitive prices. Large-scale linkers from kilograms are synthesized based on GMP, and laboratory-scale from milligrams to grams. Some linker types include but are not limited to non-cleavable linkers and cleavable linkers.
In the construction of ADCs, the specific combination of linkers and cytotoxins is most likely to differentiate the efficacy of ADC drugs and patented. As an experienced manufacturer in ADC conjugation and process amplification, BOC Sciences can supply mature linker and cytotoxic technology to accurately control the ADC coupling process in a GMP environment with complete QA/QC supervision.
Linkers are essential parts of ADCs, which connect mAbs to payloads and stabilize circulation until ADCs reach target cells for payload releases. BOC Sciences offers flexible ADC linker product suites and development services at competitive prices. Large-scale linkers from kilograms are synthesized based on GMP, and laboratory-scale from milligrams to grams. Some linker types include but are not limited to non-cleavable linkers and cleavable linkers.
BOC Sciences offers robust ADC manufacturing capabilities designed to support the entire production lifecycle, from early-stage development to large-scale cGMP manufacturing. Our manufacturing services can meet clinical and commercial development needs and equip cGMP and ISO-certified contract manufacturing facilities. Leveraging advanced facilities and a team of specialized scientists, we provide efficient and customizable solutions to meet unique client needs. Our service encompasses all essential steps, including antibody production, linker-payload synthesis, conjugation optimization, and rigorous quality control.
Scheme Design and Contract Customization
Payload/Linker Synthesis
Screening Combinations and Conjugation
Analysis, Purification and Characterization
cGMP Manufacturing and Filling
Result Delivery
BOC Sciences specializes in providing a comprehensive range of high-quality ADC products to support innovative research and development. Our offerings include custom synthesis of ADC linkers, payloads, and fully conjugated ADCs, ensuring precision and consistency. With cutting-edge facilities and strict quality control, we deliver tailored solutions for pharmaceutical and biotechnology applications. BOC Sciences also excels in flexible production scales, competitive pricing, and rigorous cGMP compliance, meeting the demands of both preclinical and commercial projects.
BOC Sciences offers a comprehensive portfolio of ADC cytotoxins, designed to meet the stringent requirements of ADC development. Our expertise encompasses the synthesis of a wide range of highly potent cytotoxic agents, including auristatins, maytansinoids, calicheamicins, and more. With advanced manufacturing facilities and strict quality control measures, we ensure the production of cytotoxins with high purity, stability, and activity.
Our extensive portfolio includes cleavable and non-cleavable linkers, such as hydrazone, disulfide, peptide, and PEG-based linkers, tailored to enhance ADC stability and drug release efficiency. With cutting-edge facilities and a team of experts, we provide custom synthesis and scalable production to meet diverse project requirements. Stringent quality control ensures each linker meets the highest purity and performance standards.
BOC Sciences excels in providing ADC cytotoxins with linkers, offering fully integrated solutions for ADC development. With advanced synthesis platforms and strict quality control, we deliver high-purity products that meet the demands of preclinical and commercial projects. Our expertise allows for custom design and scalable production tailored to your specific requirements. Partner with BOC Sciences to accelerate your ADC innovation with reliable, high-performance cytotoxin-linker solutions.
BOC Sciences provides end-to-end solutions for ADC assembly, enabling the seamless integration of antibodies, linkers, and cytotoxins into fully functional ADCs. Our advanced conjugation technologies ensure precise DARs and optimal stability, tailored to specific project requirements. Supported by state-of-the-art facilities and cGMP-compliant processes, we deliver high-quality ADCs for both preclinical and commercial-scale applications.
References
